Evidence map›Paper›PMID 33203393›Full record

ArticleBMC cancer2020

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.

Hironaga Satake, Koji Ando, Eiji Oki, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Masaki Mori

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Current Targeted Therapy for Metastatic Colorectal Cancer.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Hironaga SatakeCancer Treatment Center, Kansai Medical University Hospital, Hirakata, 573-1191, Japan.
Koji AndoDepartment of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, 812-8582, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, 812-8582, Japan. okieiji@surg2.med.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-9763-9366
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, 755-0046, Japan.
Akitaka MakiyamaCancer Center, Gifu University Hospital, Gifu, 501-1194, Japan.
Hiroshi SaekiDepartment of General Surgical Science Graduate School of Medicine, Gunma University, Maebashi, 371-8511, Japan.
Akihito TsujiDepartment of Clinical Oncology, Faculty of Medicine, Kagawa University, Miki-cho, 540-0006, Japan.
Masaki MoriDepartment of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, 812-8582, Japan.
Kyushu University · JPGifu University Hospital · JPGunma University · JPKagawa University · JPKansai Medical University · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combination. Here, we describe our planning for the EFFORT study to investigate whether FOLFIRI plus aflibercept has efficacy following FOLFOXIRI plus bevacizumab for mCRC.

methodsEFFORT is an open-label, multicenter, single arm phase II study to evaluate whether a FOLFIRI plus aflibercept has efficacy following FOLFOXIRI plus bevacizumab for mCRC. Patients with unresectable or metastatic colorectal cancer who received FOLFOXIRI plus bevacizumab as a first-line therapy will receive aflibercept and FOLFIRI (aflibercept 4 mg/kg, irinotecan 150 mg/m DISCUSSION: This is the first study to investigate whether FOLFIRI plus aflibercept has efficacy following FOLFOXIRI plus bevacizumab for unresectable or metastatic colorectal cancer. Switching to a different type of anti-VEGF drug in second-line therapy after FOLFOXIRI plus bevacizumab appears to be an attractive treatment strategy when considering survival benefit. It is expected that this phase II study will prove the efficacy of this strategy and that a biomarker for drug selection will be discovered.

trial registrationJapan Registry of Clinical Trials jRCTs071190003 . Registered April 18, 2019.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabClinical Trials, Phase II as TopicColorectal NeoplasmsFemaleFluorouracilFollow-Up StudiesHumansIrinotecanLevoleucovorinMaleMiddle AgedMulticenter Studies as TopicafliberceptBevacizumabFluorouracilIrinotecanLevoleucovorinOxaliplatinReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAnti-VEGF drugBevacizumabColorectal cancerFOLFIRIFOLFOXIRISecond line

Identifiers

PMID33203393
PMCPMC7672899
OpenAlexW3103562921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.